Sanofi

TrumpRx — the government’s drug pricing initiative, which is at the center of the tariff deals the administration has reached with drugmakers since September —...

Sanofi ( (SNY) ) just unveiled an announcement. On January 29, 2026, Sanofi reported that in 2025 it delivered strong top- and bottom-line growth, with full-ye...

Ocular Launches, And Then Yo-Yoes, On Rumors Sanofi Is Preparing A Bigger Bid 1/15/2026 Shares of Ocular Therapeutix launched and then yo-yoed Thursday on repo...

Sanofi SA (NASDAQ:SNY) reported fourth-quarter sales of $13.159 billion (11.30 billion euros) on Thursday, missing the consensus of $13.41 billion. Sales increa...

Business EPS was EUR 1.53, up by 26.7% at CER; 16.8% at actual exchange rates, delivering profitable growth; IFRS EPS (EUR 0.66). Reports net sales EUR 11.3B, u...

In 2026, sales are expected to grow by a high single-digit percentage at CER. Business EPS at CER is expected to grow slightly faster than sales, delivering pro...

(RTTNews) - France's equity index CAC 40 moved higher Thursday morning, supported by some encouraging earnings updates. Despite paring some gains subsequently,...

(RTTNews) - French drug major Sanofi (SNY) reported Thursday a loss in its fourth quarter, compared to prior year's profit, despite higher net sales. Looking ah...

Employees work on a production line at a Sanofi site in southwestern France. lou benoist/Agence France-Presse/Getty Images Sanofi SAN -2.77 %decrease; red down...

Sanofi SA (SNY) announced an update on their ongoing clinical study. Study Overview: Sanofi is running a late-stage clinical trial titled “A Phase 3, Randomize...